New Therapeutic Approach Could Prevent Injury to Fragile Transplanted Lungs

Loading

Northwestern Medicine scientists have discovered a potential therapeutic target in the donor lung that can prevent primary graft dysfunction (PGD) in lung transplant recipients, according to findings published in the Journal of Clinical Investigation (JCI).

GR Scott Budinger, MD, chief of Pulmonary and Critical Care in the Department of Medicine and the Ernest S. Bazley Professor of Airway Diseases, was senior author of the study. Read the full story from the Northwestern Medicine News Center.

Loading

CareDx Unveils New Patient-Centered Medication Management Features on AlloCare Mobile Health App

Loading

Integration of MedActionPlan PRO Facilitates Patient-Clinician Interaction to Improve Medication Adherence

BRISBANE, Calif.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that its AlloCare® mobile health app features expanded medication adherence and patient-provider communication capabilities resulting from the successful integration of MedActionPlan®, an acquisition made last year. Read the full press release on CareDx.com.

Loading

Kidney Transplant Rejection: What You Need to Know

Loading

Since the first kidney transplant more than 60 years ago,1 doctors have developed a deeper understanding of how to protect donated organs. With newer medications and improved management, it’s less likely transplanted kidneys will undergo rejection by the immune system.

That’s not to say doctors have completely eliminated the risk of kidney transplant rejection, though. Unfortunately, while many kidneys will last much longer, the median life of a kidney transplant is still only ten years. Understanding the risks and early warning signs of rejection gives you the best chance of a successful kidney transplant. Read the full story on CareDx.com.

Loading

New Biomarker Speeds Up Identification of Lung Disease

Loading

A new diagnostic method could help identify one of the deadliest types of interstitial lung disease (ILD) sooner, allowing for faster treatment and improved patient outcomes.

Idiopathic pulmonary fibrosis (IPF) is one of the most serious and common types of ILD, occurring most often in patients 60 and older with an average survival time of three to five years. At any given time roughly 300 patients are being treated for IPF in London, Ontario. Globally, it is the number one reason for lung transplants. Read more in Technology Networks.

Loading

CareDx Launches Personalized AlloHome Patient Monitoring Solution to Augment Pre- and Post-Transplant Care

Loading

AUGUST, 02, 2022

AlloHome Alerts Healthcare Provider of Adverse Events to Drive Earlier Interventions

BRISBANE, Calif.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the availability of AlloHome™, a pan-organ patient monitoring solution that extends care into a patient’s home by capturing a range of vital health data that can help doctors with the early identification of adverse clinical events and the ability to make preemptive measures to avoid complications pre- and post-transplantation.
Read the full press release at CareDx.com.

Loading

Shrinking Liver Tumors Before Transplant Greatly Improves Outcomes in HCC

Loading

Mount Sinai researchers have shown that shrinking liver tumors to a size that allows the patient to qualify for liver transplant results in excellent 10-year outcomes, validating current US policies for transplant eligibility.

Parissa Tabrizian, Associate Professor of Surgery at the Icahn School of Medicine at Mount Sinai, and colleagues explain in JAMA Surgery that liver transplant eligibility among people with hepatocellular carcinoma (HCC) has been guided by the Milan Criteria for more than 20 years. Read more from Inside Precision Medicine.

Loading

Bacteria in donor organs complicate immune response after transplantation

Loading

Organ transplant recipients take life-long immunosuppressive drugs to prevent their bodies from mounting an immune response against the donated organ, yet a substantial number of them still reject the organs. A new study by researchers from the University of Chicago shows that transplant recipients also mount an immune response against commensal bacteria in the organ graft, adding to the immune response against the genetic makeup of the tissue and reducing the effectiveness of immunosuppressive drugs.

The study, published today in the Journal of Clinical Investigation, also shows that this anti-microbial immune response can be triggered by immune cell memory of previous encounters with bacteria, further complicating the body’s ability to accept a lifesaving new organ. Read more in Medical Xpress here.

Loading

Death, disability from rheumatic heart disease decreased globally from 1990 to 2019

Loading

Despite an increased incidence and prevalence of rheumatic heart disease worldwide from 1990 to 2019, death and disability caused by the condition trended downward, according to data published in Arthritis Research &Therapy.

“Due to the high risks of premature morbidity, mortality and disability, [rheumatic heart disease (RHD)] remains a critical public health issue worldwide, particularly in many low-income countries,” Zejin Ou, PhD, of Guangzhou Twelfth People’s Hospital, in Guangzhou, China, and co-authors wrote. Read more in Healio.

Loading

Kidney stones, CKD connection unclear, but clinicians collaborate on treatment

Loading

It did not take long for nephrologist and kidney stone specialist David S. Goldfarb, MD, FASN, to realize that the buildup of pain radiating from the right side of his abdomen was from a kidney stone that had begun its downward migration.

And he came to the realization based on his experience with kidney stones – this was his second one – that the escalating pain meant he did not have the 30 minutes it would take by car to get to his favored hospital and employer, New York University’s Langone Health, for treatment. He told the driver – his wife – to divert to closer-by Columbia-Presbyterian Hospital. Read more in Healio.

Loading